David Marks, MD
Pulmonary Disease · San Antonio, TXNPI 1821016023
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $381,205 of the $452,504 with a category attached, or 84.2%. AstraZeneca accounts for 86.7% of it on its own, with 50 other manufacturers making up the rest. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 936 payments — averaging $483.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$392K
- GSK$36K
- Intuitive Surgical$7K
- Inspire Medical Systems, Inc.$5K
- Mallinckrodt Hospital Products Inc.$3K
- Bayer$1K
- plus $9K from 45 others
Across 332 payments — averaging $2622.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$292K
- AstraZeneca$267K
- Insmed, Inc.$80K
- Chiesi USA, Inc.$65K
- Sanofi US Services Inc.$40K
- Teva Pharmaceuticals USA, Inc.$36K
- plus $90K from 6 others
What the payments were for
- Speaking & faculty fees$381,20584%
- Travel & lodging$42,9559%
- Food & beverage$22,5335%
- Education$5,8111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$197,496
- AIRSUPRA$181,452
- TRELEGY ELLIPTA$34,395
- Da Vinci Surgical System$6,800
- DALIRESP$5,376
- Inspire$3,503
- ACTHAR$2,750
- BREZTRI AEROSPHERE$2,225
- SYMBICORT$1,300
- Adempas$1,080
- The Vest System 205 Acute Care$875
- The Monarch Airway Clearance System$875
- The Vest System Model 105 Home Care$875
- Pulmonx Endobronchial Valve EBV$845
- FASENRA$688
- Prolastin-C$266
- GLASSIA$248
- TEZSPIRE$145
- UPTRAVI$125
- DUPIXENT$125
How this compares
$452,504 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 30 | $420,839 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 338 | $318,159 |
| ZemairaAlpha-1-Proteinase Inhibitor | 21 | $224,911 |
| OpsumitMacitentan | 12 | $153,841 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 142 | $149,197 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $47,427 |
| OzempicSemaglutide | 45 | $39,649 |
| EliquisApixaban | 38 | $28,711 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $28,425 |
| SunosiSolriamfetol Hcl | 12 | $11,506 |
| JanuviaSitagliptin Phosphate | 12 | $10,525 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,047 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $8,963 |
| XareltoRivaroxaban | 11 | $7,504 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $7,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Combivent Respimat, Stiolto Respimat | $962 | $435,50456 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $35,528 | $402,973472 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $392,371 | $165,535189 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,019 | $153,84112 claims |
| MerckJanuvia, Belsomra | $29 | $15,32028 claims |
| Axsome Therapeutics, Inc.Sunosi | $177 | $11,50612 claims |
| Johnson & JohnsonXarelto | $70 | $7,50411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in San Antonio
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Ali AbediSan Antonio$269K
- Napoleon Puente CuellarSan Antonio$208K
- Soma JyothulaSan Antonio$129K
- Anoop NambiarSan Antonio$119K
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.